• Monthly
  • $25
  • $50
  • $100
  • $other
  • use PayPal

ONE WEEK TO DOUBLE YOUR DONATION!

A generous CounterPuncher has offered a $25,000 matching grant. So for this week only, whatever you can donate will be doubled up to $25,000! If you have the means, please donate! If you already have done so, thank you for your support. All contributions are tax-deductible.
FacebookTwitterRedditEmail

Meeting the Drug Industry

New Orleans.

It was 95 degrees with 99 percent humidity. The Gulf had the biggest oil spill in US history. And attendees to last week’s American Psychiatric Convention (APA) annual meeting in New Orleans had to brave 200 protestors chanting “no drugging kids for money” and “no conflicts of interest” to get into the convention hall.

Since 2008 when Congress investigated some APA psychiatrists for alleged drug industry conflicts of interest, more light has shone between the two groups, historically almost indistinguishable.

Participants at this year’s meeting, estimated at 14,000, saw conflict of interest slides before presentations and in their 240-page program book, fewer drug industry funded classes and entertainment and no gifts or free meals at the 5-day event.

“They used to wine us and dine us,” said one participant, a veteran of decades of annual meetings, ruefully.

“An SSRI maker flew my entire group to a Caribbean island,” remembered a doctor from the East coast who did not want to be identified. Anymore.

But polarizing figures were still present. Sitting next to outgoing APA president Alan F. Schatzberg, MD, even as protestors chanted outside, was Charles Nemeroff, MD, former psychiatry chairman at Emory University who was investigated by Congress for unreported GlaxoSmithKline income and left his post in disgrace. Nemeroff was signing the Textbook of Psychopharmacology which he co-edited with Schatzberg, also investigated by Congress. Schatzberg, psychiatry chairman at Stanford, consults to seven drug companies, owns stock and patents with others and is on Sanofi-Aventis’ Speakers Bureau according to the meeting’s Daily Bulletin.

Heading a symposium about schizophrenia was S. Charles Schulz, MD, psychiatry chairman at the University of Minnesota who was investigated for financial links to AstraZeneca believed to alter his scientific conclusions.

Presenting a poster about the benefits of long acting risperidone was Wayne MacFadden, MD, AstraZeneca’s US medical director for Seroquel until questions about his alleged sexual affairs with women doing research on the drug arose.

And a paper presented about attention deficit hyperactivity disorder (ADHD) was co-written by Harvard’s Joseph Biederman, MD, also investigated by Congress for drug industry financial links and considered the father of the pediatric bipolar disorder craze.

Despite the thaw in drug industry bennies, exhibition displays were still pretty gee-whiz with Cymbalta, Seroquel XR, Abilify, Lunesta and Pristiq the most prominent. (A rep struggled to explain to a group from Columbia that Pristiq was not, repeat not, just a more expensive Effexor.) ADHD drugs was also big. “Let’s be as brave as the people we serve” said a Shire display, showing a patient’s giant, valiant face; another of its displays reconstructed a children’s bedroom to sell INTUNIV.

But where take-one signs once existed, signs now warned health care providers they may be governed by no gift policies. And whereas glad-handing reps were still eager to answer questions — once they scanned badges for marketing data — they referred pharmacodynamic and patient care questions to an “information booth” where a real doctor, looking less pleasant, stood.

Nor was there a star of the show. The Next Big Thing was not a new drug at all but adjunctive therapy also known as adding existing drugs to existing drugs because they don’t work right. Throwing good drugs after bad, popularized with the antipsychotic Abilify, has only been enhanced by a study in the January JAMA that found antidepressants don’t work for mild depression at all. Antipsychotics are also being “enhanced” by adding drugs to offset weight gain and lethargic side effects.

No wonder panelists at a forum called “Is a Game Changing Psychotropic Too Much to Expect?” assailed drug industry for issuing “me too” drugs and “seat of the pants” drug combinations, calling the industry nothing but a “marketing organization.”

No wonder a Canadian physician castigated the FDA’s Jing Zhang for approving drugs for “competitive reasons” not patient health in a symposium about comparative drug effectiveness. “In a recent transcript on your web site, Dr. Laughren [FDA director of psychiatry products] clutches at studies to try to approve a new drug on behalf of industry,” he charged. “FDA’s non-inferiority studies in which a drug can be less effective that an existing one and only beat placebo, present the ‘patient risk’ of a drug not working,” he said.

But elsewhere drugs were given a better spin.

Ann Childress, MD, gave a veritable commercial for the ADHD drug Vyvanse, manufactured by Shire on whose Speaker’s Bureau she serves. And the Wyeth funded C. Neill Epperson, MD, appearing with Wyeth Speakers Bureau member Claudio Soares, MD, actually told a clinician in the audience not to trust a pharmacist for a hormone preparation but to use drug industry preparations in a symposium called “Mood, Memory and Myths: What Really Happens at Menopause.” Biodentical hormones, compounded by pharmacists, have been a revenue threat for Wyeth’s menopause drugs. (The seminar’s pro hormone therapy message crumbled when breast cancer patients in the audience discussed their “chemo” and “tamoxifen brain.”)

If there were a take home message at the APA meeting about the blizzard of ADHD, bipolar and personality disorders threatening adults and children, it was don’t wait. These dangerous conditions, no different from cancer and diabetes, won’t go away.

Thanks to genetic advancements, psychiatric disease risks can now be detected and treated before symptoms surface, said presenters, fostering early treatment paradigms that are pretty Brave New World: People being told they have a disease they can’t feel that needs immediate and lifelong treatment at hundreds of dollars a month or their health will suffer. Run that past me again? The National Institute on Drug Abuse is even working on vaccines to treat the specific genetic risks in opioid addicts. Good luck with that.

Not everyone agreed about early treatment. The very fact that bipolar disorder is a lifelong disease is reason to wait until you are sure said Mark Zimmerman, MD director of outpatient psychiatry at Rhode Island Hospital whose research, published in the June Journal of Nervous and Mental Disease, finds a link between unconfirmed, overdiagnosed cases of bipolar disorder and the receipt of disability payments.

Not everyone agreed about multidrug combinations commonly called polypharmacy either. In between industry “research” in poster sessions extolling Seroquel, Vyvanse, Saphris, Geodon, Risperdal and Zyprexa was a study at Maimonides Medical Center in Brooklyn “Evaluating Antipsychotic Polypharmacy Regimens for Patients with Chronic Mental Illness.”

When 24 patients on polypharmacy combinations of Seroquel, Zyprexa and other antipsychotics were reduced to only one drug — monotherapy — there was no worsening of symptoms or increased hospitalizations in 23. Not only did patients not deteriorate, their waist circumferences and triglycerides improved, say the researchers as drug interactions, side effects and, of course, cost of treatment declined.

“These are interesting data,” said a young female psychiatrist viewing the poster. “Normally clinicians are afraid to take such patients off polypharmacy.”

So is the drug industry.

 

 

WORDS THAT STICK

 

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

bernie-the-sandernistas-cover-344x550
October 16, 2019
Patrick Cockburn
How Turkey’s Invasion of Syria Backfired on Erdogan
Chitrangada Choudhury – Aniket Aga
How Cotton Became a Headache in the Age of Climate Chaos
Jack Rasmus
US-China Mini-Trade Deal: Trump Takes the Money and Runs
Michael Welton
Communist Dictatorship in Our Midst
Robert Hunziker
Extinction Rebellion Sweeps the World
Peter A. Coclanis
Donald Trump as Artist
Chris Floyd
Byzantium Now: Time-Warping From Justinian to Trump
Steve Klinger
In For a Dime, in For a Dollar
Gary Leupp
The Maria Ramirez Story
Kim C. Domenico
It Serves Us Right To Suffer: Breaking Down Neoliberal Complacency
Kiley Blackman
Wildlife Killing Contests are Unethical
Colin Todhunter
Bayer Shareholders: Put Health and Nature First and Stop Funding This Company!
Andrés Castro
Looking Normal in Kew Gardens
October 15, 2019
Victor Grossman
The Berlin Wall, Thirty Years Later
Raouf Halaby
Kurdish Massacres: One of Britain’s Many Original Sins
Robert Fisk
Trump and Erdogan have Much in Common – and the Kurds will be the Tragic Victims of Their Idiocy
Ron Jacobs
Betrayal in the Levant
Wilma Salgado
Ecuador: Lenin Moreno’s Government Sacrifices the Poor to Satisfy the IMF
Ralph Nader
The Congress Has to Draw the Line
William A. Cohn
The Don Fought the Law…
John W. Whitehead
One Man Against the Monster: John Lennon vs. the Deep State
Lara Merling – Leo Baunach
Sovereign Debt Restructuring: Not Falling Prey to Vultures
Norman Solomon
The More Joe Biden Stumbles, the More Corporate Democrats Freak Out
Jim Britell
The Problem With Partnerships and Roundtables
Howard Lisnoff
More Incitement to Violence by Trump’s Fellow Travelers
Binoy Kampmark
University Woes: the Managerial Class Gets Uppity
Joe Emersberger
Media Smears, Political Persecution Set the Stage for Austerity and the Backlash Against It in Ecuador
Thomas Mountain
Ethiopia’s Abiy Ahmed Wins Nobel Peace Prize, But It Takes Two to Make Peace
Wim Laven
Citizens Must Remove Trump From Office
October 14, 2019
Ann Robertson - Bill Leumer
Class Struggle is Still the Issue
Mike Miller
Global Climate Strike: From Protest To Power?
Patrick Cockburn
As Turkey Prepares to Slice Through Syria, the US has Cleared a New Breeding Ground for Isis
John Feffer
Trump’s Undeclared State of Emergency
Dean Baker
The Economics and Politics of Financial Transactions Taxes and Wealth Taxes
Jonah Raskin
What Evil Empire?
Nino Pagliccia
The Apotheosis of Emperors
Evaggelos Vallianatos
A Passion for Writing
Basav Sen
The Oil Despots
Brett Wilkins
‘No Friend But the Mountains’: A History of US Betrayal of the Kurds
John Kendall Hawkins
Assange: Enema of the State
Scott Owen
Truth, Justice and Life
Thomas Knapp
“The Grid” is the Problem, Not the Solution
Rob Kall
Republicans Are Going to Remove Trump Soon
Cesar Chelala
Lebanon, Dreamland
Weekend Edition
October 11, 2019
Friday - Sunday
Becky Grant
CounterPunch in Peril?
FacebookTwitterRedditEmail